Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19
Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19
Randomized controlled trial to analyse adjuvant therapeutic plasma exchange (TPE) in severe
 Covid-19 associated coagulopathy and systemic inflammation compared to current standard of
 care (SOC).

 A total of three TPEs (d1, 3, 5) will be performed in the intervention group. Primary
 endpoint is the reversibility of relative ADAMTS13 deficiency (indicated by the change in
 ADAMTS13 / VWF:Ag ratio from day 1 to 7).
Inclusion Criteria:

 -  Proven SARS-CoV2 infection

 -  Severe Covid-19 (indicated by respiratory failure requiring invasive mechanical
 ventilation)

 -  Evidence of coagulopathy (indicated by D-dimer > 10 mg/L)

 -  Evidence of systemic inflammation (CRP > 100 mg/L , ferritin > 500 ng/mL)

 Exclusion Criteria:

 -  • Participation in another study with investigational drug within the 30 days
 preceding and during the present study,

 -  Previous enrolment into the current study.

 -  Extra corporeal membrane oxygenation (ECMO)